Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial

Published:2018-04-02 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Tosco Lorenzo, ,Laenen Annouschka,Gevaert Thomas,Salmon Isabelle,Decaestecker Christine,Davicioni Elai,Buerki Christine,Claessens Frank,Swinnen Johan,Goffin Karolien,Oyen Raymond,Everaerts Wouter,Moris Lisa,De Meerleer Gert,Haustermans Karin,Joniau Steven

Funder

Janssen Pharmaceuticals

Ferring Pharmaceuticals

Leuven Cancer Institute

Fonds Yvonne Boël

European Regional Development Fund and the Walloon Region

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4275-z.pdf

Reference59 articles.

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.

2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016; https://doi.org/10.1016/j.eururo.2016.08.003 .

3. Rider JR, Sandin F, Andrén O, et al. Long-term outcomes among non-curatively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol. 2013;63(1):88–96.

4. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016;375(15):1415–24.

5. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA. 2015;314(1):80–2.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor – substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial;eBioMedicine;2023-11

2. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways;International Journal of Molecular Sciences;2023-01-20

3. Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors;Molecular Cancer Therapeutics;2022-10-10

4. Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?;Prostate Cancer and Prostatic Diseases;2022-09-09

5. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer;European Urology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3